Discovery of (2 R ,4 R )-4-(( S )-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer
Journal of Medicinal Chemistry · 12.12.2024 · 67 (23) · 20827-20841
DOI: 10.1021/acs.jmedchem.4c02309 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.11.2024. Verfasst von Scott N Mlynarski und 22 weiteren Autor:innen. Beteiligte Einrichtung: Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Arginase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Arginase is a promising immuno-oncology target that can restore the innate immune response. However, it's highly polar active site often requires potent inhibitors to mimic amino acids, leading to poor passive permeability and low oral exposure. Using structure-based drug design, we discovered a novel proline-based arginase inhibitor (10) that was potent but had low oral bioavailability in rat. This issue was addressed by incorporating amino acids to target PepT1/2 active transport, followed by in vivo hydrolysis post absorption. The hydrolysis rate was highly tunable, and the valine prodrug (19) showed the best balance of stability and exposure of the potent payload. Dosing of 19 in mouse xenograft models significantly increased arginine in the tumor microenvironment, resulting in tumor growth inhibition as a monotherapy and in combination with an anti-PD-L1 antibody. Compound 19 (AZD0011) displays good pharmacokinetics and was selected as a clinical drug candidate for cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Early Oncology R&D, AstraZeneca, Waltham 02451, Massachusetts, United States.
- Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca, Waltham 02451, Massachusetts, United States.
- Early Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
- Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, Mölndal SE-431 83, Sweden.
ORCID-Profile: Scott N Mlynarski, M Raymond V Finlay, Alwin G Schuller, Sharon Tentarelli
Zitieren
APA
Mlynarski, S. N., Aquila, B. M., Cantin, S., Cook, S., Doshi, A., Finlay, M. R. V., Gangl, E. T., Grebe, T., Gu, C., Kawatkar, S. P., Petersen, J., Pop-Damkov, P., Schuller, A. G., Shao, W., Shields, J. D., Simpson, I., Tavakoli, S., Tentarelli, S., Throner, S., …, & Ye, Q. (2024). Discovery of (2 R ,4 R )-4-(( S )-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer. Journal of Medicinal Chemistry, 67(23), 20827-20841. https://doi.org/10.1021/acs.jmedchem.4c02309
Vancouver
Mlynarski SN, Aquila BM, Cantin S, Cook S, Doshi A, Finlay MRV, et al. Discovery of (2 R ,4 R )-4-(( S )-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer. Journal of Medicinal Chemistry. 2024;67(23):20827-20841. doi:10.1021/acs.jmedchem.4c02309
BibTeX
@article{Mlynarski2024,
author = {Mlynarski, Scott N and Aquila, Brian M and Cantin, Susan and Cook, Steve and Doshi, Aatman and Finlay, M Raymond V and Gangl, Eric T and Grebe, Tyler and Gu, Chungang and Kawatkar, Sameer P and Petersen, Jens and Pop-Damkov, Petar and Schuller, Alwin G and Shao, Wenlin and Shields, Jason D and Simpson, Iain and Tavakoli, Siavash and Tentarelli, Sharon and Throner, Scott and Wang, Haixia and Wang, Jianyan and Wu, Dedong and Ye, Qing},
title = {Discovery of (2 R ,4 R )-4-(( S )-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {23},
pages = {20827--20841},
doi = {10.1021/acs.jmedchem.4c02309}
}
EUVIMED